{"id":"1177b9f1-9fb6-505b-bfbb-a5eb809e1f23","stable_key":"08ce9896-9d1c-5bbf-b705-5bfe771091d5:b7-ms-confirmatory-null","predicate":"did_not_significantly_improve","statement":"SPI2 found confirmed improvement in 39/326 biotin patients versus 29/316 placebo patients (odds ratio 1.35, 95% CI 0.81–2.26), without significant disability or walking-speed benefit.","claim_class":"observational","status":"source_derived_draft","evidence_grade":"ungraded","direction":"neutral","is_public":true,"mechanism_event_id":"ad9cfdbb-0a6f-51a0-83cc-098eef23d022","mechanism_event_label":"The larger confirmatory trial did not establish the hoped-for benefit.","subject":{"id":"37a8e96b-f95b-5ba7-a0bc-8ed3cfaf5fd8","slug":"biotin","display_name":"Biotin","entity_type_key":"small_molecule"},"object":{"id":"782076d0-7758-530e-a853-c0ad1fca1b8b","slug":"progressive-ms-disability-improvement","display_name":"Confirmed disability improvement in progressive multiple sclerosis","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"ad9cfdbb-0a6f-51a0-83cc-098eef23d022","stable_key":"08ce9896-9d1c-5bbf-b705-5bfe771091d5:b7-ms-confirmatory-null-event","event_type":"observed_intervention","label":"The larger confirmatory trial did not establish the hoped-for benefit.","description":"SPI2 found confirmed improvement in 39/326 biotin patients versus 29/316 placebo patients (odds ratio 1.35, 95% CI 0.81–2.26), without significant disability or walking-speed benefit.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"37a8e96b-f95b-5ba7-a0bc-8ed3cfaf5fd8","slug":"biotin","display_name":"Biotin","entity_type_key":"small_molecule"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"782076d0-7758-530e-a853-c0ad1fca1b8b","slug":"progressive-ms-disability-improvement","display_name":"Confirmed disability improvement in progressive multiple sclerosis","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""}]},"contexts":[{"dimension":"evidence_span","value_text":"{\"source_cache\": \"artifacts/biotin-research/33222767.abstract.txt\", \"locator\": \"Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"7665597ecbb900d0b66b45fcb92256f4d06a084811fbd914f0cdec82bd28aa00\", \"start_char\": 0, \"end_char\": 3606, \"text_sha256\": \"7665597ecbb900d0b66b45fcb92256f4d06a084811fbd914f0cdec82bd28aa00\"}","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"SPI2 randomized double-blind placebo-controlled phase 3 trial; 642 randomized adults","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"exposure","value_text":"100 mg biotin three times daily; primary improvement at month 12 confirmed at month 15","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Pharmacologic dosing in a broader cohort; results do not address nutritional replacement in deficiency. Funding and assay-interference issues were reported.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Biotin research collection; topical membership is not evidence of a direct dietary effect.","comparator":null,"unit":null,"notes":"","entity":{"slug":"biotin","display_name":"Biotin","entity_type_key":"small_molecule"}},{"dimension":"organism","value_text":"Homo sapiens","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"The larger confirmatory trial did not establish the hoped-for benefit.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"[b7-p33222767] Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial. (2020). https://pubmed.ncbi.nlm.nih.gov/33222767/ DOI: 10.1016/s1474-4422(20)30347-1","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"tissue_or_cell_type","value_text":"Progressive multiple sclerosis disability","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"b164358e-7991-51b5-8b10-04f880574ef8","evidence_kind":"source_excerpt","locator":"Lines 1209-1220","start_line":1209,"end_line":1220,"excerpt":"### b7-ms-confirmatory-null\nSPI2 found confirmed improvement in 39/326 biotin patients versus 29/316 placebo patients (odds ratio 1.35, 95% CI 0.81–2.26), without significant disability or walking-speed benefit.\nCondition category: normal\nnutrient_topic: Biotin research collection; topical membership is not evidence of a direct dietary effect.\nplain_language: The larger confirmatory trial did not establish the hoped-for benefit.\norganism: Homo sapiens\ntissue_or_cell_type: Progressive multiple sclerosis disability\nexperimental_model: SPI2 randomized double-blind placebo-controlled phase 3 trial; 642 randomized adults\nlimitations: Pharmacologic dosing in a broader cohort; results do not address nutritional replacement in deficiency. Funding and assay-interference issues were reported.\nexposure: 100 mg biotin three times daily; primary improvement at month 12 confirmed at month 15\nevidence_span: {\"source_cache\": \"artifacts/biotin-research/33222767.abstract.txt\", \"locator\": \"Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"7665597ecbb900d0b66b45fcb92256f4d06a084811fbd914f0cdec82bd28aa00\", \"start_char\": 0, \"end_char\": 3606, \"text_sha256\": \"7665597ecbb900d0b66b45fcb92256f4d06a084811fbd914f0cdec82bd28aa00\"}\n[b7-p33222767] Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial. (2020). https://pubmed.ncbi.nlm.nih.gov/33222767/ DOI: 10.1016/s1474-4422(20)30347-1","model_system":"SPI2 randomized double-blind placebo-controlled phase 3 trial; 642 randomized adults","directness":"author_interpretation","verification_status":"source_derived_draft","notes":"Exact curation-document quotation, not publisher quotation. Study references: [b7-p33222767] Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial. (2020). https://pubmed.ncbi.nlm.nih.gov/33222767/ DOI: 10.1016/s1474-4422(20)30347-1","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"9608806b-adb6-5a35-b042-057147135642","stable_key":"import-08ce9896-9d1c-5bbf-b705-5bfe771091d5","title":"Biotin: carboxylases, recycling, deficiency and nutrient interactions (2026-09-17)","document_type":"imported_text","citation_label":"AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text.","file_path":"","sha256":"a05b23a45e0813ba2fcda0027e3f5d9d58b82858f8dd8598ffb7aca17e942a38","revision_id":"e0d0c2a2-e9e2-55dd-b467-41c22ba960d4","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[{"id":"ef678c57-aa6b-536c-8811-8e9881c3edd7","title":"High-dose biotin in progressive MS: early benefit did not replicate","kind":"contradiction","status":"open","why":"The trials reached different efficacy conclusions. MS-SPI was smaller, had no placebo responders and used different eligibility and confirmation timing from the broader SPI2 trial. Those differences and random variation are candidate explanations, not proven mechanisms of the discrepant result.","resolution":"Give greater weight to the larger blinded confirmatory trial for efficacy. It did not support high-dose biotin for progressive MS. Preserve the earlier result and discuss why it did not replicate; do not turn biochemical plausibility into a proven treatment effect.","created_at":"2026-09-17 16:34:00","record_type":"conflict","display_label":"Recorded conflict","record_url":"/conflicts/ef678c57-aa6b-536c-8811-8e9881c3edd7","sides":[{"conflict_id":"ef678c57-aa6b-536c-8811-8e9881c3edd7","ordinal":0,"label":"An early trial reported benefit in a subset of patients.","revision_id":"e0d0c2a2-e9e2-55dd-b467-41c22ba960d4","start_line":1196,"end_line":1207,"quote":"### b7-ms-early-benefit\nMS-SPI reported confirmed disability improvement in 13/103 biotin-treated patients versus 0/51 placebo patients at its primary endpoint (P=0.005).\nCondition category: normal\nnutrient_topic: Biotin research collection; topical membership is not evidence of a direct dietary effect.\nplain_language: An early trial reported benefit in a subset of patients.\norganism: Homo sapiens\ntissue_or_cell_type: Progressive multiple sclerosis disability\nexperimental_model: Randomized double-blind placebo-controlled MS-SPI trial in 154 adults\nlimitations: Pharmacological exposure, not correction of proven nutritional deficiency. Small trial; larger confirmatory study did not reproduce efficacy.\nexposure: 100 mg biotin three times daily for 12 months; later open treatment\nevidence_span: {\"source_cache\": \"artifacts/biotin-research/27589059.abstract.txt\", \"locator\": \"Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"78a9ac1eb5adeeb93272160336def9e0b07684dd1eb8a12978e7fa4782e69322\", \"start_char\": 0, \"end_char\": 1333, \"text_sha256\": \"78a9ac1eb5adeeb93272160336def9e0b07684dd1eb8a12978e7fa4782e69322\"}\n[b7-p27589059] MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study. (2016). https://pubmed.ncbi.nlm.nih.gov/27589059/ DOI: 10.1177/1352458516667568","source_key":"import-08ce9896-9d1c-5bbf-b705-5bfe771091d5","source_title":"Biotin: carboxylases, recycling, deficiency and nutrient interactions (2026-09-17)","claim_ids":["c2b40ca2-daf4-59f3-aac3-7a95399e986c"]},{"conflict_id":"ef678c57-aa6b-536c-8811-8e9881c3edd7","ordinal":1,"label":"The larger confirmatory trial did not establish the hoped-for benefit.","revision_id":"e0d0c2a2-e9e2-55dd-b467-41c22ba960d4","start_line":1209,"end_line":1220,"quote":"### b7-ms-confirmatory-null\nSPI2 found confirmed improvement in 39/326 biotin patients versus 29/316 placebo patients (odds ratio 1.35, 95% CI 0.81–2.26), without significant disability or walking-speed benefit.\nCondition category: normal\nnutrient_topic: Biotin research collection; topical membership is not evidence of a direct dietary effect.\nplain_language: The larger confirmatory trial did not establish the hoped-for benefit.\norganism: Homo sapiens\ntissue_or_cell_type: Progressive multiple sclerosis disability\nexperimental_model: SPI2 randomized double-blind placebo-controlled phase 3 trial; 642 randomized adults\nlimitations: Pharmacologic dosing in a broader cohort; results do not address nutritional replacement in deficiency. Funding and assay-interference issues were reported.\nexposure: 100 mg biotin three times daily; primary improvement at month 12 confirmed at month 15\nevidence_span: {\"source_cache\": \"artifacts/biotin-research/33222767.abstract.txt\", \"locator\": \"Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"7665597ecbb900d0b66b45fcb92256f4d06a084811fbd914f0cdec82bd28aa00\", \"start_char\": 0, \"end_char\": 3606, \"text_sha256\": \"7665597ecbb900d0b66b45fcb92256f4d06a084811fbd914f0cdec82bd28aa00\"}\n[b7-p33222767] Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial. (2020). https://pubmed.ncbi.nlm.nih.gov/33222767/ DOI: 10.1016/s1474-4422(20)30347-1","source_key":"import-08ce9896-9d1c-5bbf-b705-5bfe771091d5","source_title":"Biotin: carboxylases, recycling, deficiency and nutrient interactions (2026-09-17)","claim_ids":["1177b9f1-9fb6-505b-bfbb-a5eb809e1f23"]}]}],"corrections":[],"research":null}